SOURCE: Daxor Corporation

Daxor Corporation

September 17, 2010 08:30 ET

Research Report From Study Using Daxor's Blood Volume Analyzer Presented at the 14th Annual Heart Failure Society of America Conference

NEW YORK, NY--(Marketwire - September 17, 2010) -  Daxor Corporation (NYSE Amex: DXR), a medical instrumentation and biotechnology company, today announced that a research report derived from a study using the Daxor Blood Volume Analyzer (BVA-100) was presented at the annual Heart Failure Society of America (HFSA) conference in San Diego, CA. The BVA-100 enables measurement of whole blood volume, including plasma volume and red blood cell volume. The Principal Investigator for this research study is Mathew S. Maurer, MD from the Columbia-Presbyterian Medical Center. An abstract which described his findings was published in the August 2010 Supplement (Volume 16, Issue 8) of the Journal of Cardiac Failure. The complete presentation is available on Daxor's website at

Anemia is common in patients with Heart Failure with a Preserved Ejection Fraction (HFPEF). However, proper diagnosis of anemia using standard hemoglobin measurements can be confounded by several factors associated with blood volume distortions: First, many HFPEF patients show an expansion of plasma volume, which can lead to an overestimation of anemia based on standard blood tests. If patients with normal red blood cell volume are incorrectly diagnosed with anemia, it can lead to overuse of medications and an elevated red blood cell count -- which might predispose to other medical conditions, including stroke. Conversely, some of these patients are chronically treated with diuretics, which contract their plasma volumes, and could thereby result in an underdiagnosis of anemia. Previous studies have shown that untreated anemia in heart failure patients is associated with a higher death rate. 

Dr. Maurer's study, titled "Racial Differences in Blood Volumes in Patients with Heart Failure and a Preserved Ejection Fraction: Implications for Diagnosing Anemia," examined the prevalence of anemia in a population of 60 HFPEF patients. The study compared the rate of anemia based on the standard hemoglobin blood test -- which is subject to distortion due to blood volume derangements -- with the rate of anemia found by direct blood volume measurement using the BVA-100. It found that the two methods of diagnosing anemia led to significantly different results: Anemia defined by the standard hemoglobin test was present in 68% of subjects, and did not differ based on gender or race. In contrast, when direct blood volume measurement was used to diagnose anemia, it detected anemia in only 34% of patients. This indicates that the standard hemoglobin blood test results in a two-fold overdiagnosis of anemia in this patient population. Moreover, direct blood volume measurement identified ethnic differences in the prevalence of anemia, with Black HFPEF patients showing more than twice the rate of anemia of Hispanics. These ethnic differences in the prevalence of anemia appear to be due, in part, to a significantly greater plasma volume compensation in response to red blood cell deficit in Hispanics than in Blacks. These findings may have important implications for the proper diagnosis and management of anemia in ethnic minorities with HFPEF.

The following investigators were involved in this study: Bassel Noumi, MD, Sergio Teruya, MD, Stephen Helmke, RDCS, and Mathew S. Maurer, MD. Further details can be viewed on Daxor's website. 

Daxor Corporation manufactures and markets the BVA-100, a semi-automated Blood Volume Analyzer. The BVA-100 is used in conjunction with Volumex, Daxor's single use diagnostic kit. For more information regarding Daxor Corporation's Blood Volume Analyzer BVA-100, visit Daxor's website

Contact Information